Skip to main content
. 2009 Feb 19;100(5):940–947. doi: 10.1111/j.1349-7006.2009.01119.x

Figure 3.

Figure 3

c‐FLIPL siRNA sensitized lung cancer cell lines to AD5‐10‐induced cell death. (a) H460 cells were transfected with c‐FLIPL siRNAs (siFL1, siFL2, siFL3) or non‐silencing siRNA for 24 h and then treated with or without AD5‐10 (50 ng/mL) for 24 h and cell viability was assayed. Columns, mean of three triplicate samples, and experiments were repeated three times; bars, SD; *, P < 0.05. (b) c‐FLIPL siRNA enhanced lung cancer cell viability reduction induced by AD5‐10. Indicated lung cancer cell line was transfected with non‐silencing or c‐FLIPL siRNA (siFL1) and then treated with or without AD5‐10 (50 ng/mL) for 24 h and cell viability was assayed. Columns, mean of three triplicate samples, and experiments were repeated three times; bars, SD. Insets show levels of c‐FLIPL protein in cells transfected with non‐silencing or c‐FLIPL siRNA (siFL1). Representative results of at least three different experiments shown. (c) Western blot analysis for the activation of caspase‐10, caspase‐8, caspase‐9, caspase‐3 and cleavage of Poly ADP‐ribose polymerase (PARP) in H460 cells.